A recently created services arm at drug-discovery firm Galapagos will help Novartis Pharmaceuticals UK develop and conduct functional assays in primary human cells in an undisclosed disease area, the company said this week.

Under the terms of the agreement, the services division, called Galádeno, will use its SilenceSelect gene knockdown platform to design a research program for Novartis. SilenceSelect is based on Galádeno's collection of adenoviruses with human gene sequences that knock down more than 4,000 human proteins by producing siRNA in human cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.